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Abstract
Objective. Treatment delays and suboptimal adherence to
posttreatment surveillance may adversely affect head and
neck cancer (HNC) outcomes. Such challenges can be exa-
cerbated in safety-net settings that struggle with limited
resources and serve a disproportionate number of patients
vulnerable to gaps in care. This study aims to characterize
treatment delays and adherence with posttreatment surveil-
lance in HNC care at an urban tertiary care public hospital
in San Francisco.
Study Design. Retrospective chart review.
Setting. Urban tertiary care public hospital in San Francisco.
Subjects and Methods. We identified all cases of HNC diag-
nosed from 2008 to 2010 through the electronic medical
record. We abstracted data, including patient characteristics,
disease characteristics, pathology and radiology findings, treat-
ment details, posttreatment follow-up, and clinical outcomes.
Results. We included 64 patients. Median time from diagnosis
to treatment initiation (DTI) was 57 days for all patients, 54
days for patients undergoing surgery only, 49 days for
patients undergoing surgery followed by adjuvant radiation
6 chemotherapy, 65 days for patients undergoing definitive
radiation 6 chemotherapy, and 29 days for patients under-
going neoadjuvant chemotherapy followed by radiation or
chemoradiation. Overall, 69% of patients completed recom-
mended treatment. Forty-two of 61 (69%) patients demon-
strated adherence to posttreatment visits in year 1; this fell
to 14 out of 30 patients (47%) by year 5.
Conclusion. DTI was persistently prolonged in this study com-
pared with prior studies in other public hospital settings.
Adherence to posttreatment surveillance was suboptimal and
continued to decline as the surveillance period progressed.
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D
espite significant advancements in diagnosis and
treatment in recent years, the prognosis of head and
neck cancer (HNC) remains poor, with an overall
5-year survival rate of 56% in whites and 34% in African
Americans.1 Early detection of symptoms and initiation of
therapy, as well as careful posttreatment surveillance, have
been shown to be vital for achieving optimal outcomes.
Therefore, close monitoring of patients to reduce treatment
delay and optimize adherence to posttreatment surveillance
is an important aspect of HNC care.
Racial, ethnic, and income disparities in head and neck
cancer outcomes exist and may be mitigated by close
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monitoring both during and after treatment. For example, a
2009 study by Gourin and Podolsky2 investigated racial dis-
parities between black and white patients with HNC at a
single large institution in the South and found that black
patients had significantly shorter follow-up periods com-
pared to whites. Close monitoring in the treatment and post-
treatment periods may help decrease loss to follow-up in
such vulnerable populations. Monitoring may also play an
important role in reducing delays and increasing patient
adherence to radiation therapy. A 2017 study by Thomas
et al3 showed that low-income patients experienced dispro-
portionately increased radiation treatment interruptions com-
pared to patients insured by commercial carriers or Medicare.
We chose to study treatment delays and adherence to
posttreatment surveillance in an urban safety-net hospital in
San Francisco that serves a disproportionate number of
racial and ethnic minorities and low-income patients. An
understanding of these gaps will help delineate a potential
role for a health information technology tool aimed at
improving treatment planning and monitoring of patients
with HNC in safety-net settings.
Methods
Population
We initiated this retrospective chart review as a readily
accessible, rich source of existing data to document where
gaps in care or loss to follow-up occur in HNC within an
urban safety-net hospital in San Francisco. The UCSF
Human Research Protection Program Institutional Review
Board approved this retrospective review of patient data and
waived the requirement for informed consent (#12-09658).
We identified all cases (n = 64) of biopsy-proven HNC
between 2008 and 2010 from the electronic medical record.
We excluded patients from this study if they presented with
distant metastasis, were recommended palliative treatment
as an initial treatment plan, or had no notes in the electronic
medical record documenting a clinical encounter in the oto-
laryngology clinic.
Data Collection
Using REDCap, we created a measurement tool with struc-
tured fields for data abstraction. Five researchers were
trained to ensure consistent coding through review of the
variables, protocol, and data abstraction form. At least 2
researchers abstracted each patient record, and whenever
present, discrepancies were noted and discussed to ensure
agreement between abstractors. Data abstraction consisted
of patient characteristics, disease characteristics, pathology
and radiology findings, treatment details, posttreatment
follow-up, and clinical outcomes including survival, recur-
rence, and development of a second primary tumor.
Researchers consulted the National Center for Health
Statistics’ National Death Index to supplement mortality
data for patients no longer seen at this hospital.
Data Analysis
We used descriptive statistics to report patient and disease
characteristics, treatment details, surveillance outcomes, and
clinical outcomes. Medians, as well as ranges wherever possi-
ble, were calculated for continuous variables. Number and per-
centages were calculated for categorical data. Observations
were censored for all time-to-event analyses. We performed
all statistical analyses using Excel (Microsoft, Redmond,
Washington) and Stata (StataCorp LP, College Station, Texas).
Results
Patient Demographic and Disease Characteristics
Patient demographic and disease characteristics are depicted
in Table 1. Sixty-four patients met criteria for inclusion in
this study. Fifty-three (83%) patients were men. At least 38
(59%) patients were of ethnic minorities, predominantly
Asian and African American. Thirty-one (48%) patients
were either uninsured or held low-income health insurance
(Healthy San Francisco or Medi-Cal). There was a high pre-
valence of documented housing instability (n = 15, 24%),
smoking (n = 54, 84%), alcohol abuse (n = 27, 42%), and
other drug abuse (n = 19, 30%). Fifty (78%) patients had a
Charlson comorbidity index greater than or equal to 3.4
Most tumors were located in the oropharynx (n = 30,
47%), nasopharynx (n = 21, 33%), and oral cavity (n = 9,
14%). Of the oropharyngeal tumors, 57% tested positive for
p16. It should be noted, however, that during this time
period at our institution, not all oropharyngeal tumors were
routinely tested for p16. Fifty-one (80%) patients presented
with stage III or stage IV disease. The majority of patients
underwent radiation 6 chemotherapy (n = 46, 72%), while
a smaller number had surgery followed by adjuvant radia-
tion 6 chemotherapy (n = 9, 14%), surgery alone (n = 5,
8%), or neoadjuvant chemotherapy followed by radiation or
chemoradiation (n = 4, 6%).
Median follow-up time, defined as the time from diagno-
sis to last attended otolaryngology clinic visit, was 2.6 years
(range, 19 days to 8.1 years).
Pretreatment and Treatment Measures
We performed censoring for all time-to-event analyses.
Among all patients, the median diagnosis to treatment initia-
tion interval (DTI) was 57 days. This was most prolonged
in patients undergoing definitive radiation 6 chemotherapy
(median, 65 days). DTI was shorter in patients undergoing
surgery followed by adjuvant radiation 6 chemotherapy
(median, 49 days), patients undergoing surgery alone
(median, 54 days), and patients undergoing neoadjuvant
chemotherapy followed by radiation or chemoradiation
(median, 29 days). For patients who required pretreatment
dental extraction, the median diagnosis to dental extraction
interval was 62 days. Forty-four (69%) patients studied
completed treatment (Table 2). Eleven patients failed to
start treatment. Treatment completion status of 1 patient
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could not be ascertained due to incomplete information in
the chart.
Fifty-five patients were recommended a treatment plan
involving either primary or adjuvant radiation (Table 3).
The median radiation treatment length for all patients was
49 days (range, 2-67). Eighty-two percent and 80% of
patients received the recommended dose and number of
fractions of radiation, respectively.
Adherence to Posttreatment Surveillance
Table 4 displays adherence to posttreatment surveillance
during the first 5 years after treatment completion. We
defined adherence according to the National Comprehensive
Cancer Network (NCCN) guidelines as follows for each
year after treatment: at least 4 visits attended in year 1, at
least 2 visits attended in year 2, and at least 1.5 visits
attended annually in years 3 through 5.5 Given anecdotally
increased adherence to surveillance among patients with
nasopharyngeal cancer, we examined this group of patients
separately. For all cancers, we observed a decline in adher-
ence as the surveillance period progressed. We observed a
higher adherence in patients with nasopharyngeal cancers in
years 1 through 3 of surveillance, which was no longer seen
in years 4 and 5.
Clinical Outcomes
Twenty-eight (44%) patients died during the study period
(Table 5). Of these 28 deaths, 16 (57%) were attributable
to HNC. Median time to death was 2.5 years (interquartile
range, 1.2-6.0). One- and 2-year survival were 83% and
69%, respectively. Eight (13%) patients developed 1 recur-
rence, and 3 (5%) patients developed a second recurrence.
Four (6%) patients developed a second primary cancer.
Discussion
Our findings demonstrate that safety-net health systems
need to be prepared to address a more socially and medi-
cally challenging population during and after HNC treat-
ment compared to health systems that care for more
advantaged populations. This patient population had a high
prevalence of behavioral factors associated with poor HNC
outcomes, such as tobacco use, alcohol and other substance
abuse, and homelessness. Prior studies have demonstrated
that these are risk factors for poor HNC outcomes.2 This
cohort also demonstrated a significant burden of medical
comorbidities that can interfere with treatment completion
and ability to adhere to posttreatment surveillance. With
regard to disease characteristics, a greater proportion of
patients in this population presented with advanced disease
compared to national data. A 2009 National Cancer
Database update reported a 42% prevalence of stage III and
IV disease, whereas 80% of patients in this study presented
with stage III and IV disease.6
This study found a median DTI of 57 days among all
patients. This is persistently prolonged compared to earlier
studies conducted among similar populations. A study by
Patel and Brennan7 found a DTI of 48 days among 150
Table 1. Patient and Disease Characteristics.
Total (N = 64)
Characteristics No. %
Age, median (range), y 54 (26-80)
Sex
Male 53 83
Female 11 17
Race
Asian 22 34
White 20 31
African American 9 14
Other 7 11
Unknown 6 9
Ethnicity
Not Hispanic or Latino 63 98
Hispanic or Latino 1 2
Primary language
English 29 45
Unknown 22 34
Cantonese 11 17
Spanish 1 2
Other 1 2
Insurance
Medi-Cal 20 31
Medicare 20 31
Other coverage 9 14
Healthy San Francisco 7 11
Uninsured 4 6
Unknown 4 6
Housing status
History of being marginally housed 8 13
History of homelessness 7 11
Smoking status
Former smoker 32 50
Smoker at diagnosis 22 34
History of alcohol abuse 27 42
History of other drug abuse 19 30
History of HIV/AIDS 2 3
Charlson comorbidity index
1-2 14 22
3-4 28 44
5 22 34
Patient diagnosed at outside hospital 9 14
Site
Oropharynx 30 47
Nasopharynx 21 33
Oral cavity 9 14
Salivary gland 2 3
Hypopharynx 2 3
Tumor stage at diagnosis (TNM Staging
System, seventh edition)
T1 11 17
T2 15 23
T3 12 19
(continued)
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patients treated for HNC at John H. Stroger Cook County
Hospital, an urban tertiary care public hospital in Chicago.
A study among patients with oropharynx and nasopharynx
cancer at the Zuckerberg San Francisco General Hospital
and Trauma center, the same institution in our current
study, found a DTI that ranged from 56 to 70 days depend-
ing on the tumor site.8 A prolonged DTI has been shown to
adversely affect survival—in a study of over 50,000 patients
with HNC, a DTI of 61 to 90 days vs less than 30 days
independently increased mortality risk on multivariate anal-
ysis.9 This is especially relevant among a patient population
in whom advanced stage at presentation, behavioral factors,
and burden of medical comorbidities already limit the suc-
cess of treatment.
Similar to previous studies, DTI in this study was most
prolonged among patients treated with definitive radiation
therapy.7 This is not surprising given the high level of care
coordination required for patients undergoing definitive
radiation for advanced cancer, which often involves multi-
disciplinary discussion between the otolaryngologist, radia-
tion oncologist, oral and maxillofacial surgeon, and medical
oncologist in a tumor board forum. A health information
technology tool may be able to play a role in facilitating
such multidisciplinary care coordination in a more timely
fashion. The time from diagnosis to dental extraction was
also observed to contribute substantially to DTI. This under-
scores the importance of expediting dental evaluation and
extraction to decrease DTI. Given that untreated dental dis-
ease is more prevalent in racial/ethnic minorities and low-
income patients, providing access to timely dental care is of
particular importance in this population.10
Interestingly, radiation adherence in this study compared
favorably to previously published measures among similar
populations. In a study by Patel et al11 conducted at Stroger
Hospital, 59% of patients undergoing radiation therapy
received less than the effective dose of 65 Gray. In the present
Table 1. (continued)
Total (N = 64)
Characteristics No. %
T4 10 16
T4a 7 11
T4b 5 8
Tx 4 6
Nodal stage at diagnosis (TNM Staging
System, seventh edition)
N0 10 16
N1 7 11
N2 31 48
N3 10 16
Nx 6 9
Clinical stage grouping at diagnosis
I 1 2
II 8 13
III 9 14
IV 1 2
IVa 27 42
IVb 14 22
Unknown 4 6
p16 positive 17 27
Among patients with oropharynx cancers 17 57
EBV positive 17 27
Among patients with nasopharynx cancers 17 100
Initial treatment plan
Radiation 6 chemotherapy 46 72
Surgery followed by adjuvant radiation
6 chemotherapy
9 14
Surgery 5 8
Neoadjuvant chemotherapy followed
by radiation or chemoradiation
4 6
Abbreviations: EBV, Epstein Barr Virus; HIV, human immunodeficiency virus.
Table 2. Pretreatment and Treatment Measures.
Measure No. Median
Days from diagnosis to dental extraction 42 62
Days from diagnosis to treatment initiation 64 57
Surgery 5 54
Surgery followed by adjuvant radiation 6 chemotherapy 9 49
Radiation 6 chemotherapy 46 65
Neoadjuvant chemotherapy followed by radiation or chemoradiation 4 29
No. %
Treatment completion
Patient completes recommended treatment plan 44 69
Patient does not complete recommended treatment plan 19 30
Unknown 1 2
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study, 82% and 80% of patients received the recommended
dose and number of fractions of radiation, respectively.
Institutional differences may account in part for this disparity.
Most notably, patients in this study received their radiation
treatment at a nearby affiliated academic tertiary care medical
center. Nonetheless, the ability of this vulnerable population to
achieve a relatively high radiation adherence warrants consid-
eration of how support services may be adapted in a low-
income setting to achieve favorable outcomes.
To our knowledge, this is the first study to investigate
adherence to posttreatment surveillance in a safety-net popula-
tion. At present, there are limited studies examining the impact
of posttreatment surveillance on survival in HNC. One study
by Deutschmann et al12 demonstrated that adherence to post-
treatment surveillance affected survival in HNC. However,
other studies have suggested that routine surveillance may not
contribute to a survival benefit.13,14 Nonetheless, surveillance
visits are important in screening for and managing the
Table 3. Adherence to Tumor Board Treatment Recommendations for Radiotherapy.
Characteristic No. %
Total patients recommended treatment plan involving radiation 55 100
Total patients with radiation treatment dates documented 46 84
Radiation treatment length, median (range), days 49 (2-67)
Total patients with radiation dose and frequency documented 51 93
Radiation dosage
Recommended dose delivered 42 82
Recommended dose not delivered 8 16
Unknown 1 2
Radiation frequency
Recommended fractions delivered 41 80
Recommended fractions not delivered 8 16
Unknown 2 4
Table 5. Clinical Outcomes (N = 64).
Outcome No. %
Patient death, all cause 28 44
Patient death, disease-specific 16 57
Time to death, median (interquartile range), y 2.5 (1.2, 6.0)
Survival at 1 year (95% CI) 83 (71-91)
Survival at 2 years (95% CI) 69 (55-79)
Patient develops 1 recurrence 8 13
Patient develops second recurrence 3 5
Patient develops second primary 4 6
Abbreviation: CI, confidence interval.
Table 4. Adherence to National Comprehensive Cancer Network Guidelines for Posttreatment Surveillance Visits.
No. (%)
Surveillance Year Adherent (All) Adherent (Nasopharynx) Nonadherent (All) Nonadherent (Nasopharynx)
Year 1 42 (69) 16 (76) 19 (31) 5 (24)
Year 2 37 (77) 16 (94) 11 (23) 1 (6)
Year 3 20 (59) 9 (64) 14 (41) 5 (36)
Year 4 15 (47) 6 (46) 17 (53) 7 (54)
Year 5 14 (47) 6 (46) 16 (53) 7 (54)
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complications of HNC treatment, as well as encouraging cessa-
tion of tobacco and alcohol. As such, adherence to a posttreat-
ment surveillance schedule is currently acknowledged as a
standard of care in HNC.5 Adherence to surveillance visits
may be especially difficult to achieve in a safety-net popula-
tion. In this study, adherence was highest in the first 2 years of
surveillance and declined as the surveillance period progressed.
This may require more intensive tracking and follow-up with
patients in later years. Posttreatment surveillance adherence
was analyzed separately for nasopharyngeal cancer given anec-
dotally noted higher adherence among this population. Higher
adherence to surveillance was noted in patients with nasophar-
yngeal cancer during the early surveillance period, which was
no longer seen in later years.
This study has several limitations. As a retrospective
chart review, this study is inherently prone to a number of
biases. The median follow-up period was short at 2.6 years,
which highlights the high rate of loss to follow-up in this
population that struggles with substance use, housing
instability, and medical comorbidities. In addition, particular
institutional differences may limit generalization to other
urban tertiary care public hospitals, although other hospitals
serving a safety-net population likely face similar chal-
lenges. Future studies will be required to investigate patient-
and system-related factors that contribute to treatment
delays and poor adherence to posttreatment surveillance, as
well as to elucidate how these gaps in care affect clinical
outcomes.
Conclusion
This study characterized treatment delays and adherence
with posttreatment surveillance that occur in HNC care
delivered at an urban tertiary care public hospital in San
Francisco. DTI was prolonged in this study, comparable to
earlier studies conducted among patients with HNC in other
public hospital settings. Adherence to radiation therapy com-
pared favorably to previously published measures. Adherence
to posttreatment surveillance was poor and continued to
decline as the surveillance period progressed. Further study is
needed to identify factors associated with delays and poor
adherence, as well as associated clinical outcomes.
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